Cite
A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.
MLA
Gómez, Carmen Elena, et al. “A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.” PLoS ONE, vol. 10, no. 10, Nov. 2015, pp. 1–20. EBSCOhost, https://doi.org/10.1371/journal.pone.0141456.
APA
Gómez, C. E., Perdiguero, B., García-Arriaza, J., Cepeda, V., Sánchez-Sorzano, C. Ó., Mothe, B., Jiménez, J. L., Muñoz-Fernández, M. Á., Gatell, J. M., López Bernaldo de Quirós, J. C., Brander, C., García, F., & Esteban, M. (2015). A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. PLoS ONE, 10(10), 1–20. https://doi.org/10.1371/journal.pone.0141456
Chicago
Gómez, Carmen Elena, Beatriz Perdiguero, Juan García-Arriaza, Victoria Cepeda, Carlos Óscar Sánchez-Sorzano, Beatriz Mothe, José Luis Jiménez, et al. 2015. “A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.” PLoS ONE 10 (10): 1–20. doi:10.1371/journal.pone.0141456.